Figure 5

Effect of CBL on mitochondrial proteins in Tau/GSK3β bigenic mice. (A) Immunoblot analysis of Drp-1 levels in hippocampal homogenates from vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. Actin was used as a loading control. (B) Quantitative analysis of Drp-1 levels in the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. (C) Quantitative analysis of p-Drp-1 levels in the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. (D) Immunohistochemical analysis of Drp-1 and Tom40 levels in the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. Arrows indicate immunoreactive mitochondria. (E) Quantitative analysis of Drp-1 levels in the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. (F) Quantitative analysis of Tom40 levels in the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. Scale Bars = 5 μm, Error bars represent mean ± SEM (n = 6 per group, 6 m/o). *Indicates a significant difference (p < 0.05) between vehicle non-tg mice and vehicle-treated Tau/GSK3β bigenic mice and # indicates a significant difference (p < 0.05) between vehicle and CBL treated Tau/GSK3β bigenic mice analyzed by one-way ANOVA and Dunnett’s post hoc test.